WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients

WCLC Live | Dr. Johnson: ADC Targeting B7-H3 Demonstrates Effective and Durable Response in Refractory SCLC Patients

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9-12. Dr. Melissa L. Johnson from Northwestern University's Feinberg School of Medicine presented pivotal findings on antibody-drug conjugates (ADC) for treating small cell lung cancer (SCLC). We had the privilege to interview Dr. Johnson during the conference. Here are the highlights:
Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

Dr. Wu Yilong, Dr. Cheng Ying, and Dr.Han Baohui Discuss the latest advancements in Small Cell Lung Cancer Research and Analyze the Development of ADC

For the first time in three years, Chinese experts were able to participated in the WCLC conference in person, following the end of the impact of the COVID-19 pandemic , engaging in face-to-face discussions with international scholars. Dr. Wu Yilong, Dr. Cheng Ying, and Dr. Han Baohui shared their experiences of attending the conference in Singapore.
Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both benign and malignant hematology, discussing the latest developments in the field. Regarding the treatment of Myelofibrosis (MF), several studies from Dr. Jie Jin's team at the First Affiliated Hospital of Zhejiang University (abstracts S212, P1201, and P1033) were selected for this congress. These studies focused on exploring the efficacy and safety of the new JAK inhibitor Jaktinib in the treatment of MF, attracting significant attention due to its clinical significance. In this regard, Oncology Frontier conducted an on-site interview with Professor Jin Jie and provided a brief explanation of this topic.
The Mysteries of Hepatitis D: Key Molecular Determinants in Virus Replication and Assembly

The Mysteries of Hepatitis D: Key Molecular Determinants in Virus Replication and Assembly

Dr. Wenshi Wang is the Principal Investigator of the hepatitis virus research group, Xuzhou Medical University, China. He obtained his Ph.D. from Erasmus University Rotterdam, the Netherlands, and completed post-doc research training at Heidelberg University, Germany in the field of hepatitis viruses. He has contributed more than 50 peer-reviewed publications, with 20 first or corresponding authorships in peer-reviewed academic journals such as Journal of Hepatology, Gastroenterology, Hepatology, Trends in Microbiology, Science Signaling, and JHEP Reports. He received the Kiem Award from the Royal Netherlands Society for Microbiology (2017), the EASL Sheila Sherlock Fellowship (2018) from the European Association for the Study of Liver, and the 1st Prize NVGE Gastro-intestinal Research Award from the Netherlands Society of Gastroenterology (2019). Currently, his group is committed to basic and translational research on hepatitis viruses with the following research focus:(1) Understanding the molecular and cellular mechanisms that orchestrate the hepatitis virus replication cycles; (2) Studying the host-virus interaction by employing molecular and cellular biology techniques; (3) Developing antiviral candidates and understanding their mode of action; (4) Studying the host metabolic changes and the possible consequences on virus infection.